Cencora (COR) closed at $337.84 on November 2, 2026, up 2.1% from the previous close, on volume of 1,365,633 shares (30-day average 1,135,524).
Data as of November 2, 2026.
2-Nov-2026
Globe Newswire (Mon, 2-Nov 11:20 AM ET)
Cencora (COR) Receives a Buy from Morgan Stanley
TipRanks (Fri, 30-Oct 9:07 AM ET)
Globe Newswire (Mon, 26-Oct 2:17 PM ET)
Gabelli To Host 8th Annual Healthcare Symposium
Globe Newswire (Mon, 26-Oct 8:00 AM ET)
Globe Newswire (Wed, 21-Oct 11:28 AM ET)
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
Business Wire (Wed, 21-Oct 7:30 AM ET)
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Business Wire (Fri, 2-Oct 8:00 AM ET)
Cencora Elects Robert E. Sanchez to Its Board of Directors
Business Wire (Fri, 25-Sep 8:00 AM ET)
Cencora Boosts Earnings Outlook with Broad-Based Profit Growth and Strong Segment Performance
Market Chameleon (Wed, 5-Aug 4:11 AM ET)
Cencora Reports Fiscal 2026 Third Quarter Results
Business Wire (Wed, 5-Aug 6:30 AM ET)
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of November 2, 2026, COR stock price climbed to $337.84 with 1,365,633 million shares trading.
COR has a beta of -0.03, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $64.47 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $85 billion in Revenue and $4.48 earnings per share. This beat revenue expectation by $407 million and exceeded earnings estimates by $.12.
In the last 3 years, COR traded as high as $377.54 and as low as $182.75.
The top ETF exchange traded funds that COR belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
COR has underperformed the market in the last year with a return of -0.3%, while SPY returned +11.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in COR shares. However, COR has outperformed the market in the last 3 month and 2 week periods, returning +8.4% and -0.9%, while SPY returned +1.7% and -1.5%, respectively. This indicates COR has been having a stronger performance recently.
COR support price is $326.09 and resistance is $335.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR shares will trade within this expected range on the day.